Searched over 200M research papers
10 papers analyzed
These studies suggest that right-sided congestive heart failure involves complex systemic consequences, requires careful management and surveillance, and may benefit from novel therapeutic strategies targeting underlying conditions and specific pathways.
20 papers analyzed
Right-sided congestive heart failure (RHF) is a complex condition characterized by the heart's inability to pump blood effectively, leading to systemic venous congestion. This article synthesizes current research on the causes, pathophysiology, and management of RHF, drawing from multiple studies.
RHF can arise from various conditions, including primary cardiomyopathies, right ventricular (RV) ischemia, congenital heart disease, valvular pathologies, and pulmonary hypertension, often secondary to left-sided heart disease. Pulmonary embolism and hypoxemia are common acute causes, while chronic RHF is frequently due to pulmonary hypertension.
Patients with congenital heart defects often experience RHF due to the structural abnormalities and associated pulmonary hypertension. The right ventricle may support both pulmonary and systemic circulation in these cases, leading to significant morbidity and mortality.
In veterinary medicine, RHF has been observed in dogs with conditions like degenerative mitral valve disease and dilated cardiomyopathy, where atrial fibrillation significantly increases the likelihood of RHF. Similarly, feedlot cattle have shown an increasing incidence of RHF, particularly those treated for bovine respiratory disease.
RHF is associated with decreased exercise tolerance, poor functional capacity, and progressive end-organ damage due to venous congestion and underperfusion. Chronic RHF can lead to cachexia and a systemic proinflammatory state. Hemodynamic instability is a hallmark of acute RHF, often seen in conditions like massive pulmonary embolism and RV myocardial infarction.
Pulmonary hypertension, a common precursor to RHF, leads to a complex clinical syndrome affecting multiple organ systems, including the brain, kidneys, liver, and gastrointestinal tract. This interorgan crosstalk results in reduced organ perfusion, congestion, and maladaptive neurohormonal activation, contributing to increased morbidity and mortality.
Differences between the right and left ventricles, particularly in redox signaling and oxidative stress, play a crucial role in the pathophysiology of RHF. Understanding these differences can help develop targeted therapies for RHF.
Functional assessment of the right heart is challenging due to its complex geometry. Multiple hemodynamic and biochemical markers guide clinical assessment and therapeutic decision-making. However, specific therapies targeting isolated acute and chronic RHF are lacking.
Management of RHF involves careful consideration of fluid status, preload, and afterload. In cases where medical management is ineffective, temporary mechanical circulatory support and evaluation for heart and/or lung transplantation may be necessary.
Recent research highlights the importance of the RV-gut axis in RHF pathogenesis. Visceral venous congestion can lead to gut hypoxia, altered microbiome, and increased gut permeability, contributing to systemic inflammation and cardiorenal syndrome. Therapeutic interventions targeting these pathways could offer new avenues for managing RHF.
Right-sided congestive heart failure is a multifaceted condition with diverse causes and complex pathophysiology. Effective management requires a comprehensive understanding of the underlying mechanisms and careful clinical assessment. Ongoing research into novel therapeutic strategies holds promise for improving outcomes in patients with RHF.
Most relevant research papers on this topic